CAFs are characterized by increased expression of cancer-driving growth factors, including hepatocyte growth factor (HGF) and vascular endothelial growth factor; extracellular matrix (ECM) components, such as fibronectin, collagen, and tenascin C; and enhanced contractility that influences cancer cells through mechanotransduction and ECM remodeling [1, 7]. The gene discussed is VEGFA; the disease is cancer.